Summary
Gilead Sciences, Inc. (GILD) announced on April 25, 2006, the successful closing of a significant debt financing. The company issued $650 million in aggregate principal amount of 0.50% Convertible Senior Notes due 2011 and $650 million in aggregate principal amount of 0.625% Convertible Senior Notes due 2013. The total offering amounted to $1.3 billion, with net proceeds expected to be approximately $1.28 billion after deducting discounts and expenses. This offering was conducted through a private placement to qualified institutional buyers, relying on exemptions from registration under the Securities Act. To mitigate potential dilution from the conversion of these notes, Gilead also entered into convertible note hedge transactions and sold warrants. These complex financial instruments are designed to manage the impact on the company's stock price if the notes are converted. Investors should note the low coupon rates on the notes and the specific conditions under which conversion can occur, as well as the implications of the accompanying hedge and warrant transactions.
Key Highlights
- 1Gilead Sciences successfully closed a $1.3 billion offering of Convertible Senior Notes (0.50% due 2011 and 0.625% due 2013).
- 2Net proceeds from the offering are expected to be approximately $1.28 billion.
- 3The notes were offered via a private placement to qualified institutional buyers under Section 4(2) and Rule 144A of the Securities Act.
- 4Gilead entered into convertible note hedge transactions to offset potential dilution upon conversion, costing approximately $379.1 million.
- 5The company also sold warrants, receiving approximately $235.5 million, which affect the effective conversion price.
- 6The initial conversion prices are approximately $77.50 for the 2011 Notes and $76.20 for the 2013 Notes, subject to adjustments.
- 7The company has agreed to register the notes and underlying shares for resale under a shelf registration statement within 270 days.